Brands, Medical Use, Clinical Data
Drug Category
- Antiglaucomic Agents
- Ophthalmics
- Carbonic Anhydrase Inhibitors
Dosage Forms
Brands / Synonyms
2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (R)-; Azopt; Brinzolamide [USAN]
Indications
For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Pharmacology
Used in the treatment of glaucoma, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss.
Mechanism of Action
Brinxolamide is both a sulfonamide and a carbonic anhydrase II inhibitor. Carbonic anhydrase catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions, with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure, and thereby a reduction in the risk of optic nerve damage and glaucomatous visual field loss.
Absorption
Not Available
Toxicity
Not Available
Biotrnasformation / Drug Metabolism
Ophthalmic
Contraindications
Brinzolamide is contraindicated in patients who are hypersensitive to any component of this product.
Drug Interactions
AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor. Acid-base and electrolyte alterations were not reported in the clinical trials with brinzolamide. However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy. Therefore, the potential for such drug interaction should be considered in patients receiving AZOPT (brinzolamide ophthalmic suspension) 1%.
|